Nektar Therapeutics (NASDAQ:NKTR)’s share price hit a new 52-week high on Friday . The stock traded as high as $58.48 and last traded at $57.42, with a volume of 810700 shares trading hands. The stock had previously closed at $57.88.

Several equities analysts have recently weighed in on the stock. Canaccord Genuity increased their price objective on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, November 13th. Canaccord Genuity Group increased their price objective on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday, November 15th. Roth Capital set a $45.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 13th. Mizuho raised their price target on shares of Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and set a $44.00 price target on shares of Nektar Therapeutics in a research report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $35.58.

The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The business had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. During the same period last year, the company earned ($0.32) EPS. The firm’s revenue was up 321.2% compared to the same quarter last year. equities research analysts anticipate that Nektar Therapeutics will post -0.75 earnings per share for the current year.

In other news, SVP Ivan P. Gergel sold 100,000 shares of Nektar Therapeutics stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $24.14, for a total value of $2,414,000.00. Following the completion of the sale, the senior vice president now owns 84,871 shares in the company, valued at approximately $2,048,785.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Stephen K. Doberstein sold 43,677 shares of Nektar Therapeutics stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $24.97, for a total transaction of $1,090,614.69. The disclosure for this sale can be found here. Insiders sold a total of 931,027 shares of company stock worth $27,283,000 in the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System increased its position in shares of Nektar Therapeutics by 1.0% in the second quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company’s stock worth $1,582,000 after purchasing an additional 800 shares during the last quarter. State of Wisconsin Investment Board bought a new position in shares of Nektar Therapeutics in the second quarter worth approximately $2,248,000. Bank of New York Mellon Corp increased its position in shares of Nektar Therapeutics by 0.6% in the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock worth $41,812,000 after purchasing an additional 12,730 shares during the last quarter. Tocqueville Asset Management L.P. increased its position in shares of Nektar Therapeutics by 8.5% in the third quarter. Tocqueville Asset Management L.P. now owns 252,202 shares of the biopharmaceutical company’s stock worth $6,053,000 after purchasing an additional 19,800 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Nektar Therapeutics by 9.1% in the second quarter. Ameriprise Financial Inc. now owns 952,443 shares of the biopharmaceutical company’s stock worth $18,620,000 after purchasing an additional 79,510 shares during the last quarter. 96.01% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Sets New 12-Month High at $58.48” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/22/nektar-therapeutics-nktr-sets-new-12-month-high-at-58-48.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.